AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis

Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against atopic dermatitis (AD). The company has secured a No Objection Letter from Health Canada, authorizing its Clinical Trial Application for ABCL575, a next-generation monoclonal antibody designed for moderate-to-severe AD and potentially other autoimmune and inflammatory diseases.

AbCellera Biologics Inc. (ABCL) Receives Health Canada Approval for Phase 1 Trial of ABCL575 in Atopic Dermatitis

A research scientist examining a biological sample to develop a new drug candidate.

ABCL575 stands out as an Fc-silenced, half-life extended antibody that targets the OX40 ligand, a key player in the inflammatory pathways that drive AD. By disrupting the OX40/OX40L interaction, ABCL575 aims to suppress T cell-mediated inflammation, a hallmark of the disease. Preclinical studies have demonstrated the antibody’s potent anti-inflammatory effects, strong safety profile, and an extended half-life, which could allow for less frequent dosing compared to existing therapies.

The upcoming Phase 1 trial, set to launch in the third quarter of 2025, will assess the safety and pharmacokinetics of ABCL575 in healthy volunteers via subcutaneous administration. AbCellera Biologics Inc. (NASDAQ:ABCL)’s innovative approach could mark a significant advancement in the treatment landscape for atopic dermatitis and related immune disorders.

While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.